A photo of Rashmi Hegde.

Professor, UC Department of Pediatrics



Biography & Affiliation


Rashmi Hegde received her PhD in medicinal chemistry from the University of Pittsburgh in 1989. She received post-doctoral training in the Department of Molecular Biophysics and Biochemistry at Yale University, where she was a fellow of the National Cancer Center. She was appointed assistant professor of biochemistry at New York University School of Medicine and the Skirball Institute of Biomolecular Medicine in 1994. She is presently a full professor in the Division of Developmental Biology at Children's Hospital Research Foundation within the Department of Pediatrics at the University of Cincinnati College of Medicine.

Clinical Interests

Pre-clinical validation of anti-angiogenic agents for use in the treatment of retinopathies, cancer and pulmonary disease.

Research Interests

Molecular mechanisms involved in normal development and in disease states using in vitro (cellular and solution biochemistry and structural biology) and in vivo (mouse models) strategies; developing novel therapeutic strategies via structure-aided drug design coupled with in vitro validation and in vivo pre-clinical studies.

Academic Affiliation

Professor, UC Department of Pediatrics


Developmental Biology

Science Blog

New Drug Target for a Fatal Lung Disease

Heart and Lung

New Drug Target for a Fatal Lung Disease

Rashmi S. Hegde, PhD9/12/2019


PhD: University of Pittsburgh, Pittsburgh, PA, 1989.

Post-doctoral Fellowship: Yale University, 1989-1994.

Assistant Professor: New York University School of Medicine, Skirball Institute, 1994-2000.

Associate Professor: Cincinnati Children's Hospital Medical Center, 2001-2007.

Professor: Cincinnati Children's Hospital Medical Center, 2008-present.


Selected Publication

The Initiation of Meiotic Sex Chromosome Inactivation Sequesters DNA Damage Signaling from Autosomes in Mouse Spermatogenesis. Abe, H; Alavattam, KG; Hu, Y; Pang, Q; Andreassen, PR; Hegde, RS; Namekawa, SH. Current Biology. 2020; 30:408-420.e5.

The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension. Wang, Y; Pandey, RN; York, AJ; Mallela, J; Nichols, WC; Hu, Y; Molkentin, JD; Wikenheiser-Brokamp, KA; Hegde, RS. Nature Communications. 2019; 10.

An opsin 5-dopamine pathway mediates light-dependent vascular development in the eye. Nguyen, MT; Vemaraju, S; Nayak, G; Odaka, Y; Buhr, ED; Alonzo, N; Tran, U; Batie, M; Upton, BA; Darvas, M; et al. Nature Cell Biology. 2019; 21:420-429.

The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth. Wang, Y; Pandey, RN; Riffle, S; Chintala, H; Wikenheiser-Brokamp, KA; Hegde, RS. Molecular Cancer Therapeutics. 2018; 17:1659-1669.

Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids. Riffle, S; Pandey, RN; Albert, M; Hegde, RS. BMC Cancer. 2017; 17.

The Eyes Absent Proteins in Developmental and Pathological Angiogenesis. Wang, Y; Tadjuidje, E; Pandey, RN; III, SJ A; Smith, LE H; Lang, RA; Hegde, RS. The American journal of pathology. 2016; 186:568-578.

The Eyes Absent proteins in development and disease. Tadjuidje, E; Hegde, RS. Cellular and Molecular Life Sciences. 2013; 70:1897-1913.

A direct and melanopsin-dependent fetal light response regulates mouse eye development. Rao, S; Chun, C; Fan, J; Kofron, JM; Yang, MB; Hegde, RS; Ferrara, N; Copenhagen, DR; Lang, RA. Nature. 2013; 494:243-246.

The EYA Tyrosine Phosphatase Activity Is Pro-Angiogenic and Is Inhibited by Benzbromarone. Tadjuidje, E; Sen Wang, T; Pandey, RN; Sumanas, S; Lang, RA; Hegde, RS. PLoS ONE. 2012; 7:e34806-e34806.

The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Pandey, RN; Rani, R; Yeo, E; Spencer, M; Hu, S; Lang, RA; Hegde, RS. Oncogene: Including Oncogene Reviews. 2010; 29:3715-3722.